U

University of Wisconsin | Department of Ophthalmology and Visual Sciences - Clinical Eye Research Unit

Research site
(Unclaimed)
Location
2828 Marshall Court, Suite 106, Madison, Wisconsin, United States of America
Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

63 of 582
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
18F-FLUC-CEST PET/MR in Patients With Brain Mets

The goal of this clinical trial is to use new imaging methods to help in finding out whether the imaging shows that there is a tumor in people with a...

Enrolling
Immunotherapy, Active
Radiation Therapy
Radiation: F-Fluciclovine radiotracer

The aim of this study is to evaluate the safety and efficacy of 67Cu-SARTATE in pediatric patients with high-risk neuroblastoma.

Enrolling
Refractory Neuroblastoma
Relapsed Neuroblastoma
Drug: 64Cu-SARTATE
Drug: 67Cu-SARTATE

The main purpose of this study is to evaluate the safety, recommended dose, and preliminary anti-tumor activity of WU-CART-007 in patients with relap...

Active, not recruiting
T-cell Acute Lymphoblastic Leukemia
Lymphoblastic Lymphoma
Biological: WU-CART-007

This study will evaluate the safety, tolerability and efficacy of VX-880 infusion in participants with Type 1 diabetes mellitus (T1D) and impaired aw...

Enrolling
Diabetes Mellitus, Type 1
Impaired Hypoglycemic Awareness
Biological: VX-880
Locations recently updated

This is a Phase III, global, randomized, open-label, multicenter, study evaluating the efficacy and safety of adjuvant giredestrant compared with end...

Enrolling
Early Breast Cancer
Drug: Endocrine Therapy of Physician's Choice
Drug: Abemaciclib

This Phase III, randomized, double-blind, placebo-controlled, multicenter study will evaluate the efficacy and safety of giredestrant combined with p...

Active, not recruiting
Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer
Drug: Letrozole
Drug: Giredestrant-matched Placebo

This study is to determine the maximum tolerated dose (MTD) and the recommended Phase 2 dose (RP2D) and to investigate the safety, pharmacokinetics (...

Enrolling
Solid Tumor
Drug: NDI-101150
Drug: Pembrolizumab

The purpose of this study is to characterize the safety, tolerability, and efficacy of IDE161.

Enrolling
Breast Cancer
Pancreas Cancer
Drug: IDE-161

The design of a phase I, open-label, dose finding study was chosen in order to establish a safe and tolerated dose of single agent WVT078 alone and i...

Active, not recruiting
Multiple Myeloma (MM)
Drug: WHG626
Biological: WVT078

To evaluate the efficacy of naporafenib administered with trametinib in patients with rat sarcoma viral oncogene (RAS) Q61X solid tumorsTo evaluate t...

Enrolling
Advanced or Metastatic Solid Tumors
Drug: Trametinib
Drug: Naporafenib

The purpose of this study is to evaluate the safety and tolerability of CFT1946 as well as to determine the maximum tolerated dose (MTD) and/or the r...

Enrolling
ATC
Melanoma
Drug: Trametinib
Drug: CFT1946

The primary objective of this study is to evaluate motor function following treatment with HD nusinersen in participants with spinal muscular atrophy...

Enrolling
Spinal Muscular Atrophy
Drug: Nusinersen

This is a Phase 1, open-label, dose-escalation, and dose-expansion, with a gated randomization portion, study to evaluate the safety, tolerability, p...

Active, not recruiting
Advanced Pancreatic Cancer
Drug: Zimberelimab
Drug: Gemcitabine
Locations recently updated

This study is open to adults with a lung disease called Idiopathic Pulmonary Fibrosis (IPF). People can join the study if they are 40 years or older....

Active, not recruiting
Idiopathic Pulmonary Fibrosis
Drug: Placebo
Drug: BI 1015550
Locations recently updated

This study is open to adults with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs). People who have a form of PF-ILD other than Idiopathic...

Active, not recruiting
Lung Diseases, Interstitial
Drug: Placebo
Drug: BI 1015550

The investigator hypothesizes that treating osteoporotic patients with abaloparatide prior to and after total knee arthroplasty will significantly re...

Active, not recruiting
Osteoporosis
Arthroplasties, Knee Replacement
Drug: Abaloparatide

The vast majority of patients with stage I (tumors ≥ 4cm), IIA, IIB (and select stage III) NSCLC are managed with upfront surgery, followed by adjuva...

Enrolling
Lung Cancer
NSCLC
Drug: Atezolizumab
Drug: Cisplatin

The primary purpose of this study is to determine whether treatment with lecanemab is superior to placebo on change from baseline of the Preclinical...

Enrolling
Preclinical Alzheimer's Disease
Early Preclinical Alzheimer's Disease
Drug: Lecanemab
Drug: Placebo

Patients who have histologically confirmed metastatic or unresectable (not amenable to curative therapy) breast cancer may be screened for eligibilit...

Enrolling
PIK3CA Mutant Metastatic Breast Cancer
HER2-negative Breast Cancer
Drug: Alpelisib
Drug: Fulvestrant

A Phase II, multi-center, single-arm, non-blinded study combining androgen deprivation therapy (ADT) and pembrolizumab for patients with metastatic o...

Enrolling
Salivary Gland Carcinoma
Drug: Goserelin Acetate
Drug: Pembrolizumab

Trial conditions

Breast Cancer (22 trials)
Fibrosis (17 trials)
Heart Failure (16 trials)
Lung Cancer (16 trials)
Cancer (16 trials)
Prostatic Cancer (16 trials)
Cystic Fibrosis (14 trials)
Non-Small-Cell Lung Carc... (13 trials)
Alzheimer Disease (12 trials)
Lymphoma (12 trials)

And 90 more

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems